Curcumin: Updated Molecular Mechanisms and Intervention Targets in Human Lung Cancer by Ye, Ming-Xiang et al.
Int. J. Mol. Sci. 2012, 13, 3959-3978; doi:10.3390/ijms13033959 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Review 
Curcumin: Updated Molecular Mechanisms and Intervention 
Targets in Human Lung Cancer 
Ming-Xiang Ye 
1,†, Yan Li 
2,†, Hong Yin 
3,* and Jian Zhang 
1,* 
1  Department of Pulmonary Medicine, Detection Center of Tumor Biomarker, Xijing Hospital, 
Fourth Military Medical University, 710032 Xi’an, China; E-Mail: mingxiangye@yahoo.cn 
2  Department of Pulmonary Medicine, First People’s Hospital of Xi’an, 710032 Xi’an, China;  
E-Mail: huliyan1971@126.com 
3  Department of Radiology, Medical Imaging Center, Xijing Hospital, Fourth Military Medical 
University, 710032 Xi’an, China 
†  These authors contributed equally to this work. 
*  Authors to whom correspondence should be addressed; E-Mails: yinhong@yahoo.com (H.Y.); 
zhangjian197011@gmail.com (J.Z.); Tel./Fax: +86-29-84775237 (H.Y.);  
Tel./Fax: +86-29-84771132 (J.Z.). 
Received: 6 February 2012; in revised form: 5 March 2012 / Accepted: 15 March 2012 / 
Published: 22 March 2012 
 
Abstract: Curcumin, a yellow pigment derived from Curcuma longa Linn, has attracted 
great  interest  in  the  research  of  cancer  during  the  past  decades.  Extensive  studies 
documented  that  curcumin  attenuates  cancer  cell  proliferation  and  promotes  apoptosis 
in vivo and in vitro. Curcumin has been demonstrated to interact with multiple molecules 
and  signal  pathways,  which  makes  it  a  potential  adjuvant  anti-cancer  agent  to 
chemotherapy. Previous investigations focus on the mechanisms of action for curcumin, 
which is shown to manipulate transcription factors and induce apoptosis in various kinds of 
human cancer. Apart from transcription factors and apoptosis, emerging studies shed light 
on  latent  targets  of  curcumin  against  epidermal  growth  factor  receptor  (EGFR), 
microRNAs (miRNA), autophagy and cancer stem cell. The present review predominantly 
discusses significance of EGFR, miRNA, autophagy and cancer stem cell in lung cancer 
therapy. Curcumin as a natural phytochemicals could communicate with these novel targets 
and show synergism to chemotherapy. Additionally, curcumin is well tolerated in humans. 
Therefore,  EGFR-,  miRNA-,  autophagy-  and  cancer  stem  cell-based  therapy  in  the 
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presence  of  curcumin  might  be  promising  mechanisms  and  targets  in  the  therapeutic 
strategy of lung cancer. 
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1. Introduction 
Lung  cancer  is  the  leading  cause  of  cancer  related  mortality  worldwide,  with  approximately  
one point six million new cases and one point four million deaths each year [1]. The prognosis of lung 
cancer is poor because lung cancer can be symptomless in the early stage and the patients usually 
consult clinicians when distant metastases are already present. Over the past decades, lung cancer has 
switched from an untreatable disease with a dismal outcome to one that has increasing numbers of 
chemotherapeutic  regimens  and  individualized  treatment  options  available.  There  has  been  a 
significant improvement in the overall survival time for lung cancer patients since the emergence of 
well-established systemic chemotherapy strategies and newer approaches to achieve disease control. 
However, chemotherapy as the backbone for lung cancer has shown weak therapeutic results because 
of  deleterious  adverse  effects  and  the  possibility  of  cancer  recurrence  after  drug  withdrawal.  In 
addition, the development of multidrug resistance has  greatly limited the life-expanding effects of 
chemotherapeutic agents with less than 15% patients reaching five years of survival [2]. Therefore, 
searching new therapeutic agents and exploring novel intervention targets might provide more clinical 
benefits and indicate better outcomes in lung cancer therapy. 
Having  established  chemopreventive  activities  and  preclinical  anti-cancer  effects,  numerous 
naturally occurring phytochemicals provide novel therapeutic approaches and treatment alternatives. 
Vinblastine  from  Vinca  rosea  is  one  of  the  earliest  examples  that  originated  from  medical  herbs 
prescribed for cancer, and paclitaxel is perhaps one of the most recent examples that originates from a 
Chinese  pacific  yew  plant.  Other  plant-derived  anti-cancer  agents  include  etoposide,  teniposide, 
homoharringtonine and camptothecin derivatives. These bioactive phytochemicals exert their anti-cancer 
activities mainly through inducing cell cycle arrest and triggering cancer cell apoptosis. Among nearly 
600 kinds of phytochemicals, curcumin (diferuloylmethane), a yellow spice and phenolic compound 
derived from the plant Curcuma longa, is one of the most powerful and promising chemopreventive 
and anti-cancer agents. Both epidemiological evidence and clinical trials have demonstrated that the 
consumption  of  a  curcumin-rich  diet  has  is  inversely  correlated  with  certain  types  of  human 
malignancies [3–5]. Extensive studies have revealed the mechanisms of action of curcumin as an anti-cancer 
agent, in which NF-κB, STAT3, COX-2, NOS, ROS, Akt (defined as transcription factors), anti-apoptotic 
proteins,  growth  factor  receptor  and  multidrug-resistance  proteins  (defined  as  apoptosis  related 
molecules) are involved [6–11]. The rapid evolution in cancer research has driven a new understanding 
of cancer biology and set novel therapeutic targets. Meanwhile, a growing number of evidence shows 
that curcumin affects many more targets and multiple mechanisms in cancer cells.  
The present review focuses on the roles of epidermal growth factor receptor (EGFR), microRNAs 
(miRNAs), autophagy and cancer stem cells in lung cancer therapy, and provides a synopsis of the 
association of curcumin and these recently established targets (Figure 1). Therapeutic strategies being Int. J. Mol. Sci. 2012, 13  
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implemented to target EGFR, miRNAs, autophagy and cancer stem cells are discussed, including the 
use of curcumin in lung cancer. 
Figure 1. Currently well established targets (red bubbles) and potential novel targets (green 
bubbles) for curcumin in human lung cancer. 
 
2. Curcumin and Acquired Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase  
(TKIs) Resistance 
Epidermal growth factor receptor (EGFR) is a member of the family of growth factor receptors 
tyrosine kinases (TKs) that play a crucial role in cell proliferation, division and differentiation. Upon 
EGFR activation, the downstream intracellular signaling cascades such as the PI3K/Akt, Raf/MEK/Erk, 
and STAT pathways are subsequently activated leading cell survival. Aberrant EGFR expression and 
signaling are found in various kinds of human cancers. Somatic mutations in exon 19 and exon 21 
encoding the EGFR TKs domain are found in about 10% of non-small cell lung cancer (NSCLC) in the 
United  States,  with  78.8%  frequency  in  the  Chinese  populations  with  lung  adenocarcinoma  [12]. 
NSCLC  patients  harboring  exon  19  deletion  or  exon  21  L858R  somatic  mutations  experience 
significant tumor regression when prescribed the reversible small molecular tyrosine kinase inhibitors 
(TKIs)  such  as  gefitinib  and  erlotinib.  Discovery  of  EGFR-TKIs  which  is  based  on  the  novel 
understanding of biological mechanisms underlying lung cancer development is a breakthrough in the 
therapeutic strategy of thoracic oncology. The median times to progression in the advanced NSCLC 
range from 9.4 to 13.3 months after EGFR-TKIs treatment is three- to fourfold greater than with 
conventional  platin-based  chemotherapy  [13–15].  Unfortunately,  nearly  all  NSCLC  patients  who 
possess activating mutations and initially respond well to EGFR-TKIs, eventually procede to disease 
progression within 6–12 months after EGFR-TKIs treatment. This acquired EGFR-TKIs resistance is 
closely  associated  with  a  secondary  mutation  in  EGFR.  EGFR  T790M  (threonine  to  methionine 
mutation at codon 790 of EGFR) gatekeeper mutation is the most common mechanism of acquired 
resistance to EGFR-TKIs and it has been detected in over 50% of resistant NSCLC patients and from 
EGFR-TKIs resistant cell lines [16–18] (Figure 2). The precise mechanisms of EGFR T790M-mediated 
acquired EGFR-TKIs resistance are not yet fully understood. To date, EGFR T790M leads to steric 
hindrance and interferences with the EGFR-TKIs binding in the ATP kinase binding pocket [19]. In 
this respect, it has been shown that second generation irreversible EGFR-TKIs, including HKI-272, 
BIBW2992 and PF00299804, partly overcome acquired resistance in cell lines harboring EGFR T790M 
in several pre-clinical studies [20–22]. Int. J. Mol. Sci. 2012, 13  
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Another  mechanism  related  to  acquired  EGFR-TKIs  resistance  involves  amplification  of  MET, 
which has been reported in around 20% of acquired resistant patients. MET protein is a TK that is over 
expressed in various types of cancer cells, including lung cancer. The ability of MET to induce EGFR-TKIs 
resistance  was  correlated  well  with  its  mitogenic,  motogenic,  morphogenic,  and  anti-apoptotic 
properties [23,24]. Continuous administration of gefitinib or erlotinib in lung cancer patients with 
MET amplification did not interrupt tumor progression, regardless of EGFR status. Conversely, several 
MET inhibitors promoted NSCLC cell apoptosis and potentially reversed EGFR-TKIs resistance [25,26]. 
In a study performed by Yano et al., the authors demonstrated that MET restored persistent PI3K/Akt 
signaling pathways, independent of EGFR status, thus inducing gefitinib resistance of lung cancer cells 
bearing EGFR-activating mutations [27]. In this regard, MET inhibitors have raised a broader interest 
in their therapeutic indications in cancer. In particular, Engelman et al. showed that a MET inhibitor 
PHA-665752 could restore cellular sensitivity to EGFR-TKIs [28]. 
Both established resistant mechanisms lead to sustained TKs downstream PI3K/Akt signaling in the 
presence of EGFR-TKIs [29,30]. Therefore, concomitant inhibition of EGFR and MET is required to 
eliminate  the  resistant  cells  and  reverse  EGFR-TKIs  resistance.  Treatment  of  cancer  cells  with 
curcumin  results  in  a  dose-  and  time-dependent  inhibition  of  cell  proliferation  associated  with 
curcumin’s epigenetic modulation of target genes and proteins [31–33]. Existing evidence suggest that 
curcumin  acts  as  an  epigenetic  agent  through  interaction  with  histone  deacetylases,  histone 
acetyltransferases  and  DNA  methyltransferases  [34].  However,  the  precise  mechanisms  by  which 
curcumin modulates gene expression have not yet been fully delineated. One potential theory is that 
curcumin produces integrated modulation of intracellular signal transduction and transcription factors. 
Nuclear factor kappaB (NF-κB) is a generally accepted predominant epigenetic target of curcumin. 
Numerous lines of evidence have suggested curcumin suppressed cancer cell proliferation by reducing 
NF-κB signaling and its genetic targets, including cyclin D1, c-myc, Bcl-2, Bcl-xl, CIAP-1, COX-2, 
VEGF and matrix metalloproteinase (MMP)  [35,36]. Activated protein-1 (AP-1) is  a transcription 
factor  that  transactivates  c-met  promoter.  C-met  gene  expression  is  also  inducible  by  its  ligand 
hepatocyte growth factor (HGF). Seol et al. reported that curcumin inhibited AP-1 activity and blocked 
its transactivation of the c-met promoter. Moreover, induction of the endogenous c-met gene by HGF 
was inhibited by the addition of curcumin as well [37]. Down-regulation of c-met by administration of 
curcumin might provide potential targets to overcome MET-dependent EGFR-TKIs resistant mechanisms. 
For EGFR mRNA and protein, several other transcription factors have been recently recognized. 
Curcumin dose-dependently suppressed EGFR mRNA and protein expressions in three lines of human 
colon cancer-derived cells. Luciferase reporter assay and electrophoretic mobility shift assay indicated 
that curcumin interrupted trans-activation activity of transcription factor Egr-1 in the EGFR promoter 
as  a  putative  mechanism  in  regulating  EGFR  expression  [38].  Similarly,  curcumin  repressed 
transcription  factor  Sp,  which  promoted  EGFR  expression,  and  showed  a  synergistic  effect  with 
gefitinib in KU7 and 253JB-V human bladder cancer cells [39]. Collectively, these reports highlighted 
the epigenetic profile of curcumin and supported it as a potent modulator for EGFR transcription 
factors. Suppression of EGFR mRNA and its protein product using curcumin’s epigenetic activity 
would block the downstream tyrosine kinase signaling cascade and overcome acquired EGFR-TKIs 
resistance (Figure 2). Compared with inhibiting EGFR downstream signal transduction by EGFR-TKIs, 
direct removal of this receptor seems to offer more therapeutic effects. And this newly established anti-Int. J. Mol. Sci. 2012, 13  
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cancer  mechanism  of  curcumin  might  provide  more  clinical  benefits  especially  in  lung  cancer, 
regardless of EGFR mutation status. 
Figure 2. The gene structure of epidermal growth factor receptor (EGFR) and the genetic 
targets for curcumin and epidermal growth factor receptor-tyrosine kinase (EGFR-TKIs). 
Exons  1–16  encode  the  EGFR  extracellular  domain  (green),  exons  17–18  encode  the 
transmembrane domain (gray) and exons 19–21 encode the tyrosine kinase domain (red). 
Cancer cells harboring deletions in exon 19 or L858R mutation in exon 21 are sensitive to 
EGFR-TKIs (red arrows indicated). Secondary T790M mutation in exon 20 is a mechanism 
of acquired EGFR-TKIs resistance (black arrow indicated). Two transcription factors Egr-1 
and Sp bind to EGFR gene promoter and accelerate EGFR mRNA transcription. Whereas 
curcumin attenuates Egr-1 and Sp binding and inhibites EGFR mRNA expressions. 
 
Conversely, in  a  recent study,  Lee  and colleagues  investigated the  EGFR degradation-inducing 
potential of curcumin in the primary and acquired EGFR-TKIs resistant cell lines (CL1-5 and A549, 
EGFR wide type; H1975, EGFRL858R + T790M). The IC50 of gefitinib for these resistant cells at  
72 h (15–20 μM) was up to nearly 700-fold when compared with the EGFR-TKIs sensitive PC-9 cells 
(EGFR19del) (IC50 = 30 nM). The resistant cell proliferation was significantly inhibited when gefitinib 
and curcumin were used in combination. Pre-treatment with curcumin also dose-dependently reduced 
phosphor-EGFR protein expression, and its downstream signaling was stimulated by exogenous EGF. 
Interestingly, the endogenous EGFR was dramatically depleted in response to curcumin in the three 
gefitinib resistant cells as well [40]. Immuno-precipitation data showed that curcumin induced EGFR 
protein degradation by accelerating ubiquitin-proteasome ability in wide type EGFR (CL1-5 and A549) 
and also in the mutated EGFR with T790M (H1975). In further support of the data, when experiments 
were performed in tumor-bearing SCID mice, administration of curcumin inhibited growth of CL1-5, 
A549  and  H1975  xenografts  and  enhanced  the  anti-tumor  efficiency  of  gefitinib.  Curcumin 
simultaneously down-regulated oncogenic protein expression, in particular Akt and c-MET in CL1-5 
xenograft  models.  Since  EGFR-TKIs  inevitably  caused  undesirable  gastrointestinal  side  effects, 
gefitinib single agent  in combination with  curcumin therapies were evaluated for potent intestinal 
damage in vivo and in vitro. Combined treatment reduced gefitinib-induced villi damage and apoptosis 
in mice intestines [40].  
Taken together, all of the abovementioned studies indicate a potent role of curcumin in overcoming 
resistance supported by EGFR-TKIs in NSCLC. Herein we raised the hypothesis that curcumin as an Int. J. Mol. Sci. 2012, 13  
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adjuvant therapeutic agent in both primary and secondary EGFR-TKIs resistant NSCLC cells, at least 
in  part,  for  its  epigenetic  activity  on  EGFR  expression.  Promoting  ubiquitin-proteasome-mediated 
EGFR degradation and inhibiting EGFR downstream signaling initiated by curcumin are yet novel 
strategies that ultimately might be embraced as potential therapies for resistant NSCLC (Figure 3).  
Co-administration  of  curcumin  and  EGFR-TKIs  attenuated  the  adverse  gastrointestinal  effects  of 
EGFR-TKIs as well as its ability to function as a chemosensitizer in NSCLC. 
Figure 3. Molecular mechanisms of EGFR-mediated cancer cell proliferation, invasion and 
metastasis. Upon activation, the extracellular domain of EGFR protein (green) transducts 
the signal into the intracellular tyrosine domain (red) through the transmembrane domain 
(gray). The PLCγ, PI3K/Akt and MAPK pathways are subsequently activated, leading to 
cancer cell proliferation, invasion and metastasis. However, in the presence of curcumin, 
EGFR protein undergoes ubiquitination and degradation. Decreased EGFR protein on the 
cell membrane attenuates proliferative, invasive and metastatic signals, leading to cancer 
cell apoptosis and death. This mechanism works regardless of EGFR mutation status. 
 
3. Curcumin and Its Epigenetic Actions on MicroRNAs 
MicroRNAs (miRNAs) are a class of short highly conserved non-coding RNAs, which undergo 
sequential  processing  by  the  RNase  III-like  enzymes  Drosha/Dicer  from  hairpin-structured 
precursors [41].  Mature  miRNAs  regulate  multiple  gene  expression  by  imperfect  complementary 
binding  to  target  mRNAs  at  the  3'-untranslated  region  (UTR),  leading  to  mRNA  cleavage  or 
translational  repression  [42].  Several  computational  algorithms  have  been  developed  to  predict 
transcript targets of miRNAs. In silico analysis suggests that miRNAs may be responsible for the 
regulation of up to one third of the genome simultaneously [43]. To date, over 800 annotated miRNAs 
have been identified in humans, yet the exact biologic relevance and functional targets of a wide range 
miRNAs  remain  undefined.  Numerous  evidence  has  revealed  miRNAs  emergence  as  key 
posttranscriptional regulators of gene expression and regulation of a variety of biological processes, 
including  development,  cell  proliferation,  differentiation  and  apoptosis  [44,45].  First  experimental Int. J. Mol. Sci. 2012, 13  
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evidence  that  suggested  that  miRNAs  might  participate  in  human  carcinogenesis  and  hit  specific 
molecular targets came from the realization of the chromosomal deletion (13q14.3) in human chronic 
lymphocytic leukemia (CLL), in which two miRNAs, miR-15a and miR16-1, were down-regulated in 
68% CLL cases [46]. Following this, a growing number of findings have also shown that miRNAs are 
implicated in all stages of cancer, from initiation to promotion and progression, and act as tumor 
suppressors or oncogenes  [47–49]. Certain miRNAs are up-regulated or down-regulated in human 
cancer, with some overlapping miRNA profiles depending on tissue origin. For example, miRNA let-7, 
targeting the oncogene ras, was down-regulated [50], while the miR-17-92 cluster at chromosome 
13q31.3 was reported to be over-expressed in lung cancer [51,52]. 
Aberrant miRNAs signatures have been observed in various kinds of human cancers. More recently, 
miRNAs have been detected in sputum and peripheral blood, which gave rise to a lot of attention for 
their potential clinical relevance in the early detection and prognostic prediction of lung cancer [53–56]. 
Forced expression or competitive suppression of aberrant miRNA can regulate the biological alteration during 
carcinogenesis, underscoring the therapeutic potential of miRNAs in lung cancer. Takamizawa et al. [50] 
firstly reported reduced expression of let-7 in human NSCLC specimens as well as in cell lines, and 
loss of let-7 was recognized as a marker for poor prognosis. Renewed or ectopic expression of let-7 in 
lung cancer cell lines inhibited cell growth. Conversely, the cluster miR-17-92 was up-regulated in lung 
cancer cells with neuroendocrine properties, in particular in small cell lung cancer [51]. Over-expression of 
miR-17-92 promoted cancer cell proliferation via interaction with tumor suppressors and transcription 
factors. Repression of miR-17-92 suppressed its oncogenic effects and elicited lung cancer cell death in 
cell lines [57]. These data indicate that therapeuticalyy inhibiting or restoring aberrantly under-expressed 
miRNAs in miRNAs-based strategies might provide potential clinical benefits as a new generation  
of therapeutics.  
Only a few reports have so far investigated the effect of curcumin on miRNAs expressions. A 
pioneering  study  from  Sun  et  al.  [58]  identified  for  the  first  time  that  curcumin  could  modulate 
miRNAs signatures in a human pancreatic carcinoma BxPC-3 cell line. They found that miR-22 was 
the most up-regulated and miR-199a* the most suppressed. The major challenge for miRNAs studies is 
to  identify the biologically relevant  downstream targets  that they regulate. The expression of two 
computationally predicted targets for miR-22, SP1 transcription factor (SP1) and estrogen receptor 1 
(ESR1), were examined. Forced expression of miR-22 by either treatment with curcumin or miR-22 
mimetics transfection inhibited the expression of SP1 and ESR1 target genes, whereas miR-22 anti-sense 
enhanced SP1 and ESR1 expressions [58]. Shortly after Sun and colleagues’ report, we identified 
miRNAs  signature  profiles  as  a  response  to  curcumin  in  human  lung  cancer  by  high-throughput 
microarray [59]. After 48 h of curcumin treatment at the concentration of 15 μmol/L, we observed that 
curcumin promoted A549 cell apoptosis through modulation of miR-186* and targeted its down-stream 
caspase-10 pathway [59]. In human colorectal cancer Rko and HCT116 cells, curcumin inhibited the 
transcriptional  regulation  of  miR-21  via  AP-1,  suppressed  cancer  cell  proliferation,  invasion  and 
metastasis, and stabilized the expression of the tumor suppressor programmed cell death protein 4 
(Pdcd4) [60]. Likewise in breast cancer MCF-7 cells, curcumin reduced the expression of Bcl-2 and 
induced apoptosis by upregulating the expression of miR-15a and miR-16 [61]. 
Furthermore, miRNAs have been reported to modulate chemotherapeutic drug resistance. Certain 
miRNAs were identified that defect in apoptosis and enable cancer cells to escape apoptosis is of Int. J. Mol. Sci. 2012, 13  
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extremely importance. Guo et al. [62] found that transfection of the drug-resistant small cell lung 
cancer cells with the mimics of miR-134 greatly increased the sensitivity to the anti-cancer drugs cisplatin, 
etoposide,  and  doxorubicin.  In  another  study,  transfecting  NSCLC  with  anti-miR-221  and  anti-miR-222 
efficiency sensitized to TRAIL, by modulating p27
kip1 and Kit [63]. Zhu et al. [64] also demonstrated 
that enforced miR-181b expression targeting the 3'UTR of BCL-2 sensitized multidrug resistant lung 
cancer  cells  to  cisplatin-induced  apoptosis.  These  findings  were  extended  to  determine  whether 
curcumin altered aberrantly expressed miRNAs as a chemosensitizer during acquired drug resistance. 
We therefore analyzed genome-wide miRNA profiling in A549/DDP multidrug-resistant human lung 
adenocarcinoma cells. We observed altered expressions of 342 miRNAs as a response to curcumin in 
A549/DDP cells, and miR-186* also emerged as the key target to reverse resistance and promote 
apoptosis [65]. Notably, a curcumin analogue CDF up-regulated miR-200 expression and down-regulated 
the  expression  of  miR-21  in  gemcitabine-resistant  pancreatic  cancer  cells,  triggering  resistant  cell 
apoptosis and down-regulation of PTEN, Akt, COX-2, prostaglandin E2, vascular endothelial growth 
factor, and NF-κB DNA binding activity [66] (Table 1). 
Table 1. Curcumin alters miRNAs and relevant target expression in pancreatic, colorectal, 
breast and lung cancers. 
Cancer Origin  Upregulate  Downregulate  Targets  Reference 
Pancrea  miR-22  miR-21  SP1, ESR1  [58] 
  miR-200  miR-199a*  PTEN  [66] 
Colorectum    miR-21  AP1, Pdcd4  [60] 
Breast  miR-15a    Bcl-2  [61] 
  miR-16       
Lung    miR-186*  Casp-10  [59,65] 
Overall, the above studies support multiple roles for individual miRNAs in regulating carcinogenesis 
and tumor progression in various human cancers. We predict that modulation of miRNAs and their 
multiple target genes by curcumin is a novel therapeutic approach to human cancer with respect to promote 
cancer cell apoptosis and overcome drugs resistance. However, these approaches are still in the in vitro 
and preclinical stages, although intriguing evidence is emerging to support latent curcumin-miRNAs 
crosstalk in clinical applications. Further in vivo and clinical trials are essential for the confirmation of 
curcumin-miRNAs-based therapeutics. 
4. Curcumin Induces Autophagy: A Double-Edged Sword in Cancer Therapy 
Apoptosis has been considered as the predominant type of programmed cell death (PCD), and the 
major form of cell death induced by chemotherapy and radiotherapy. While autophagy has attracted a 
lot of interest in the field of oncological research during the past decades because it is designated as 
PCD type II, apoptosis is well-known as PCD type I and necrosis as type III PCD. Autophagy is an 
evolutionarily  conserved  catabolic  process  typically  found  in  eukaryocytes.  It  is  morphologically 
characterized  by  sequestering  organelles  and  long-lived  proteins  in  double  membrane-bound 
autophagic  vacuoles,  also  known  as  autophagosomes.  These  autophagosomes  degrade  and  recycle 
proteins  and  defective  cellular  organelles  by  fusing  with  lysosomes  to  form  autolysosomes  [67]. Int. J. Mol. Sci. 2012, 13  
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Autophagy  allows  cells  to  survive  in  conditions  of  starvation  by  inducing  lysosomal  recycling  of 
intracellular nutrients as well as caspase-independent cell death [68].  
The distinct roles of autophagy in carcinogenesis as well as in cancer progression are still being 
elucidated, with seemingly conflicting studies suggesting that the induction of autophagy mediates 
chemotherapeutic and radiotherapeutic resistance in certain types of tumors while  it enhances  cell 
death in others. On the one side, decreased autophagic activity associated with malignant cells may be 
related to the prevention of excessive protein loss upon starvation of tumor cells [69–71]. On the other 
side, prolonged autophagy in cancer cells can also lead to autophagic PCD, provoking the possibility 
of utilizing autophagy activation for cancer therapy [72–75]. Recently, a series of published literature 
shed light on the study of autophagy in human lung cancer. Several natural and synthetic agents have 
been shown to modulate autophagy in lung cancer in vivo and in vitro [76–80]. Han et al. [79] indicated 
that lung cancer cells undergoing autophagy were resistant to EGFR-TKIs and enhanced autophagy 
was proposed to play a role in poor performance of EGFR-TKIs. In another study, however, autophagy 
facilitated cell death in lung adenocarcinoma A549 cells through interaction with p53 [81]. MG-2477 
is  a  new  anti-tubulin  agent,  causing  A549  cells  to  arrest  in  the  G2/M  phase  with  a  concomitant 
accumulation of cyclin B through its action on both apoptosis and autophagy [80]. Therefore, this topic 
has raised the question of whether manipulation of autophagy, either positively or negatively, could 
conceivably be applied for therapeutic strategies in lung cancer. 
While autophagy appears to play dual roles in certain types of cancers as discussed above, there is 
also data supporting the hypothesis that the induction of autophagy can be medicated by curcumin. In 
human chronic myeloid leukemia (CML) K562 cell line, curcumin triggers apoptosis and autophagy in 
a  caspase-dependent  and  -independent  manner,  respectively  [81].  Alternatively,  curcumin  yields 
autophagic  and  non-apoptotic  cancer  cell  death  in  oesophageal  cancer  KYSE450  and  OE19  cell  
lines [82]. It has also been found that curcumin used as a single agent or in combination with other 
cytotoxic therapeutics results in accelerated autophagosome membrane protein LC3-II expression, and 
development  of  PCD  in  malignant  glioma  and  hepatocellular  carcinoma  cell  lines  [83–87].  These 
effects  are  mediated  through  curcumin’s  inhibition  of  the  Akt/mTOR/p70S6  kinase  pathway  and 
inhibition of the ERK1/2 signaling, which are both involved in the regulation of autophagy. Activation 
of  the  Akt/mTOR/p70S6  pathway  decreases  curcumin-induced  autophagic  cell  death  as  well  as 
activates  the  ERK1/2  pathway,  which  results  in  inhibition  of  autophagy  and  induction  of  
apoptosis [85,86,88]. 
Collectively, the general conclusion has been drawn from these studies that autophagy plays a dual 
role in determining cell survival and programmed death during its dysregulation. Results from these 
studies  highlight  the  importance  of  curcumin  in  regulating  autophagy  and  the  potential  utility  of 
autophagy  as  a  means  of  predicting  therapeutic  outcome.  Although  the  role  of  curcumin-induced 
autophagy discussed above have not been fully investigated in lung cancers, the above-mentioned 
studies indicate that curcumin-induced autophagy is associated with cancer cell growth suppression 
and death, suggesting that its involvement in lung cancer is warranted and worth investigating. Int. J. Mol. Sci. 2012, 13  
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5. Targeting Cancer Stem Cell 
The  concept  of  cancer  stem  cell  (CSC)  was  initially  introduced  when  Bonnet  and  Dick  [89] 
published a seminal report showing that a hierarchical manner exists among leukemic cells which has 
gathered considerable attention over the past several years. Based on their findings, it is argued against 
the  conventional  perspectives  that  all  cells  within  a  cancer  have  equal  potential  to  propagate  the 
malignancy. The present understanding of CSC is that there is a limited subpopulation of primitive 
undifferentiated cancer cells that has the ability to self-renew, is tumorigen and invasive, undergoes 
asymmetrical divisions and generates all aspects of cancers. Dominant CSCs are in a quiescent state 
and  refractory  to  conventional  chemotherapy  and  radiotherapy  that  target  dividing  cells,  whereas 
proliferative CSCs maintain and promote the development of the cancers [90–93]. CSCs have been 
discovered in various kinds of human cancers. Focusing on lung cancer, isolation and purification of 
CSCs have been identified in lung cancer cell lines as well as from patient primary samples. Enriched 
lung  CSCs  show  highly  metastatic  and  invasive  properties  and  are  very  resistant  to  cis-platin, 
doxorubicin  and  ectoposide  [94,95].  Among  entire  lung  cancer  cells,  ALDH  (aldehyde 
dehydrogenase)-,  CD133-,  OCT4-  and  GLDC  (glycine  decarboxylase)-positive  cells  display  stem  
cell-like  activities  and  interfere  with  these  targets  and  have  been  implicated  to  promote  CSCs 
differentiation as well as elimination [96–100]. Expression of these CSCs markers is linked to shorter 
progression-free survival in clinical protocols and thus CSCs-based therapeutics might be relevant in 
sensitizing the response to chemotherapy regimens and preventing cancer metastasis and relapse [101].  
Given  these  considerations,  attempts  targeting  CSCs  and  corresponding  signaling  pathways  are 
being carried out in several preclinical studies. For example, RNA interference with Wnt/β-catenin 
signaling in lung CSCs strongly decreased cancer cell proliferation, clone formation and drug resistance 
abilities  [100].  CSCs  within  cancer  cell  populations  are  resistant  to  chemotherapeutic  agents,  but 
salinomycin selectively kills CSCs [102]. The PTEN pathway has also been effectively targeted by 
specific small molecules. It has been shown that the expression of PTEN is required for stem cell 
maintenance while the loss of PTEN is associated with an expansion of putative CSCs population. One 
study on leukemia showed that PTEN knockdown lead to over-proliferation of normal hematopoietic 
stem cells (HSCs) and the development of myeloproliferative malignancy. The inhibitor of mTOR, 
sirolimus, acts on PTEN and improves healthy HSCs replication while at the same time promotes the 
depletion of leukemia initiating cells [103]. Of equal importance, Hedgehog, JAK-STAT, Bim, Notch 
and PI3K/Akt signaling also offer latent intervention targets against CSCs [104]. Curcumin as a single agent 
or in combination with the conventional chemotherapeutic regimen could be an effective therapeutic 
strategy to prevent emergence of chemoresistant cancer cells and relapse of various cancers by eliminating 
CSCs. Recent studies in breast cancer cells demonstrated that curcumin inhibited ALDH-expressing 
breast  CSCs  self  renewal  but  did  not  cause  toxicity  to  differentiated  cells  by  suppressing  Wnt  
signaling  [105].  Likewise,  curcumin  has  been  shown  to  inhibit  CD133  positive  medulloblastoma, 
glioblastoma,  pancreatic  and  colon  CSCs  proliferation  through  insulin-like  growth  factor  (IGF)-, 
STAT3-, Hedgehog- and histone methyltransferase EZH2-dependent mechanisms [106–109]. 
Eliminating CSCs by targeting relevant signaling pathways and designing agents to inhibit these 
pathways have been somewhat successful approaches. However, these established targets participate in 
numerous physiological and pathological process and they are not cancers- and CSCs-specific. Systemic Int. J. Mol. Sci. 2012, 13  
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inhibition  of  these  signaling  pathways  could  have  serious  consequences  for  the  host.  Potential 
undesirable side effects caused by agents targeting the above-mentioned pathways should be kept in 
mind. Targeting CSCs-specific self-renewal pathways and mechanisms to delete CSCs while limiting 
mistargeting on normal stem cells and somatic cells might generate profound approaches to eliminate 
tumorigenic cells. Phytochemicals have been reported to selectively target CSCs and have no defined 
deleterious  effect  on  the  normal  stem  cells  in  a  number  of  preclinical  studies  [110,111].  These 
inspiring findings highlight a research evolution of phytomedicine in the field of oncology. Further 
CSCs-based target therapy of phytochemicals, especially for curcumin, should be cautiously evaluated 
in animal models before we can suggest it for clinical trials. Optimal strategies involving combined 
conventional  and  CSCs-based  therapies  might  kill  the  bulk  tumor  cells  while  simultaneously 
eradicating CSCs. 
6. Perspectives and Directions 
An inspiring feature of curcumin is that it is remarkable well absorbed and tolerated in animal 
models and humans. A growing number of systemic studies has shown that curcumin given at a dosage 
up to 3500 mg/kg/body weight for up to 90 days is safe in rats, dogs, or monkeys, without evident 
adverse  effects.  Curcumin  has  also  been  granted  an  acceptable  daily  intake  level  up  to  
3 mg/kg/body weight in humans by the Joint FAO/WHO Expert Committee on Food Additives [112]. 
Though  there  are  few  preclinical  studies  indicating  potential  liver  injury,  nausea  and  diarrhea  as 
deleterious responses to large doses and prolonged curcumin administration, several large scale clinical 
trials  still  show  that  curcumin  is  well  tolerated.  A  recent  phase  I  trial  in  patients  with  advanced 
colorectal cancer suggested that curcumin was well tolerated at all dose levels up to 3600 mg daily for 
up to four months [113]. In another study by Cheng et al. [110] administered 500, 1000, 2000, 4000, 
and 8000 mg curcumin daily for three months to patients with pre-invasive malignancies and found no 
noticeable  adverse  effects.  Unfortunately,  curcumin  undergoes  a  rapid  metabolism  and  systemic 
elimination, and a large proportion of curcumin and its metabolites is excreted through the feces and 
bile, leading to a relatively poor bioavailability of curcumin in vivo. Curcumin orally administered at a 
dose of 1000 mg/kg body weight to rats resulted in 75% secretion in the feces with negligible amounts 
in the urine [114]. As for human studies, 2000 mg purified curcumin powder was administered to 
fasting volunteers and low curcumin concentrations (<10 ng/mL) in plasma were observed 1 h after 
administration [115]. Interestingly, the administration of curcumin in combination with 20 mg piperine, 
an inhibitor of glucuronidation of curcumin, significantly increased the bioavailability 20-fold [116]. 
In order to enhance the pharmacological activity and bioavailability, several curcumin-based chemical 
modifications  have  been  explored.  Formulations  like  curcumin  nanoparticles,  liposomes,  micelles, 
phoshoplipid complexes and analogues have been demonstrated to provide longer circulation, increase 
the cellular permeability and induce resistance to metabolic processes [117–120].  
In summary, we have discussed a line of novel molecular mechanisms and therapeutic targets for 
curcumin,  including  EGFR  degradation,  miRNA,  autophagy  and  CSC,  in  human  lung  cancer. 
Curcumin used as a single agent or in combination with other chemotherapeutics might offer more 
clinical  benefits  through  promoting  EGFR  degradation,  manipulating  miRNA  expression  profiles, 
triggering cancer cell autophagy and eliminating CSC, respectively. Since EGFR-TKIs have several Int. J. Mol. Sci. 2012, 13  
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advantages compared with other treatment options and they are becoming a central component of first-, 
second- and third-line treatment for NSCLC, reversing and overcoming EGFR-TKIs resistance are of 
great urgency. Given that curcumin suppresses EGFR mRNA expression, promotes EGFR protein 
degradation, and precludes EGFR-TKIs toxicity of intestines injury, curcumin might offer another way 
to attenuate EGFR-related signals regardless of EGFR mutation status. Besides, curcumin, as a novel 
epigenetic agent, interacts with miRNAs implicated in cell proliferation and apoptosis. Limited data 
are available underscoring the hypothesis that curcumin facilitates the design of appropriate therapies 
targeting miRNAs; more well controlled experiments are still needed to comprehensively evaluate the 
impact of curcumin on lung cancer outcomes in an adjuvant settings. Curcumin functional-induced 
cancer cell autophagy and CSC elimination are of special interest, representing an important variable 
to  kill  cancer  cells  and  prevent  cancer  relapse,  thereby  shedding  light  on  a  new  approach  to  the 
therapeutic strategy of lung cancer.  
Overall, results from these studies highlight the importance of curcumin in lung cancer treatment 
and  the  potential  utility  of  curcumin  as  a  means  of  improving  therapeutic  outcome.  Despite  the 
potential for rationally designed therapies, confirmatory findings are required from prospective trials 
conducted in defined lung cancer patient populations. 
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